Stimulants for ADHD (Methylphenidate, Amphetamines)

USMLE Step 1 trap: Confuses methylphenidate's reuptake-blocking mechanism with amphetamine's additional monoamine-releasing mechanism. Methylphenidate blocks reuptake of dopamine and norepinephrine, while amphetamines additionally cause active release of monoamines from presynaptic terminals.

Stimulants are first-line pharmacotherapy for ADHD, and USMLE Step 1 tests them in two main ways: mechanism distinctions between drug classes and side effect profiles including contraindications. The key drugs are methylphenidate (Ritalin), amphetamine/dextroamphetamine (Adderall), and lisdexamfetamine (Vyvanse — a prodrug converted to dextroamphetamine). Students often treat these as interchangeable, but the exam specifically distinguishes how they work at the synapse.

The mechanism question is where most students lose points. Both drug classes increase dopamine and norepinephrine in the synapse, but they do it differently — and that difference matters for Step 1. Methylphenidate is purely a reuptake inhibitor (like cocaine, mechanistically). Amphetamines do that AND actively push monoamines out of presynaptic terminals via reversal of the transporter. That additional release mechanism is what the exam will ask you to identify in a vignette comparing the two.

On the side effects side, the exam tests whether you know the cardiac screening requirement before starting stimulants — not just that cardiac contraindications exist, but that a history and workup should precede initiation when there's suspicion of structural heart disease. There's also a classic misconception about growth suppression: stimulants slow height and weight gain modestly and reversibly, not permanently. Overstating this effect is a predictable trap in pediatric ADHD questions.

From real student decks

5%have cards covering this topic

3%have mature cards

A gap in most decks — fewer than half of students in our cohort have cards covering this topic.

Common misconceptions

Common mistake

Wrong: Methylphenidate and amphetamines both work by the same mechanism.

Right: Methylphenidate blocks reuptake of dopamine and norepinephrine, while amphetamines additionally cause active release of monoamines from presynaptic terminals.

Both drugs increase synaptic dopamine and norepinephrine, which makes them feel equivalent — but the mechanism is meaningfully different. Methylphenidate blocks the dopamine and norepinephrine transporters (DAT and NET), preventing reuptake, similar to how cocaine works. Amphetamines go further: they enter the presynaptic terminal and cause active reversal of DAT and NET, physically pumping monoamines out into the synapse. This release mechanism is why amphetamines have higher abuse potential and a steeper dose-response curve.

Common mistake

Gap: Missing the requirement for cardiac screening before starting stimulants in children with suspected heart disease

Stimulants are contraindicated in children with structural heart disease, and a cardiac history and ECG should be obtained before initiating therapy if cardiac abnormality is suspected.

Many students know stimulants are relatively contraindicated in structural heart disease but don't know the clinical workflow that precedes prescribing. Before starting stimulants in a child with a suspected cardiac abnormality, you should obtain a cardiac history and perform an ECG — and refer to cardiology if anything is flagged. The exam may present a child with a murmur or family history of sudden cardiac death and ask what you do before prescribing methylphenidate. The answer is screen first, not prescribe first.

Common mistake

Wrong: Stimulants permanently stunt growth in children with ADHD.

Right: Stimulants cause modest, reversible slowing of height and weight gain, not permanent growth suppression, and growth typically normalizes.

Stimulants do cause slowing of height and weight gain in children, but this effect is modest and reversible — it is not permanent stunting. Growth typically catches up when the medication is discontinued or during drug holidays. The exam may frame this as a reason to avoid stimulants entirely, which overstates the risk. The correct framing is that growth should be monitored regularly, not that stimulants are contraindicated due to growth concerns.

Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →

Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

Know the mechanistic difference between methylphenidate (reuptake blockade only) and amphetamines (reuptake blockade PLUS active monoamine release from presynaptic terminals) — the exam will ask you to distinguish them.
Know the expected side effects of stimulants (decreased appetite, insomnia, increased heart rate and blood pressure, growth slowing) and recognize that cardiac screening — including history and ECG if cardiac abnormality is suspected — is required before starting therapy in children.

Can you avoid these mistakes?

A vignette describes a drug that treats ADHD by blocking dopamine and norepinephrine transporters without causing active monoamine release. Is this methylphenidate or amphetamine, and what additional mechanism do amphetamines have?

A 9-year-old with ADHD is about to start stimulant therapy. His mother mentions a heart murmur noted at birth that was never fully worked up. What should you do before prescribing?

Parents of a child on methylphenidate for 1 year are worried because their child is in the 30th percentile for height, down from the 45th percentile before treatment. They ask if this growth suppression is permanent. What do you tell them?

Which stimulant drug class has the higher abuse liability and why — and how does that connect to the mechanism difference between methylphenidate and amphetamines?

Stimulants for ADHD (Methylphenidate, Amphetamines)

Common misconceptions

What the exam tests

Can you avoid these mistakes?

Related topics